Abstract
Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m 2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m 2 (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1707-1710 |
| Number of pages | 4 |
| Journal | Medical Oncology |
| Volume | 29 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Docetaxel
- Esophageal cancer
- Gastric cancer
- Preoperative chemotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Hematology
Cite this
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. / Bayraktar, Ulas Darda; Bayraktar, Soley; Hosein, Peter; Chen, Emerson; Koniaris, Leonidas; Caio Max, S. Rocha Lima; Montero, Alberto J.
In: Medical Oncology, Vol. 29, No. 3, 09.2012, p. 1707-1710.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma
AU - Bayraktar, Ulas Darda
AU - Bayraktar, Soley
AU - Hosein, Peter
AU - Chen, Emerson
AU - Koniaris, Leonidas
AU - Caio Max, S. Rocha Lima
AU - Montero, Alberto J.
PY - 2012/9
Y1 - 2012/9
N2 - Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m 2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m 2 (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.
AB - Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m 2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m 2 (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.
KW - Docetaxel
KW - Esophageal cancer
KW - Gastric cancer
KW - Preoperative chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=84872761801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872761801&partnerID=8YFLogxK
U2 - 10.1007/s12032-011-0093-8
DO - 10.1007/s12032-011-0093-8
M3 - Article
C2 - 22033912
AN - SCOPUS:84872761801
VL - 29
SP - 1707
EP - 1710
JO - Medical Oncology
JF - Medical Oncology
SN - 1357-0560
IS - 3
ER -